CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

Inclusion Criteria

• •The subject population that will be observed in this registry, must fulfil all of the following criteria:
• •1. Provision of subject Informed Consent
• •2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic MTC
• •3. Patients who already received a prescription for vandetanib in accordance with the scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets.
• •The prescription of the medicinal product is clearly separated from the decision to include the subject in the registry.